Alvo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alvo

Quick Facts

Property Description
Active ingredient Oxaprozin
Form Tablet or Capsule (solid oral form)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain, stiffness, and inflammation
Origin Synthetic (Propionic Acid Derivative)

What is Alvo and What Class Does it Belong To?

Alvo is a medicinal preparation whose active component, Oxaprozin, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging to the chemical group known as Propionic Acid Derivatives. This signifies it is a synthetic, single-ingredient compound designed for systemic action to moderate the body's response to inflammation and pain. Oxaprozin is administered orally in solid forms, such as a tablet or capsule.

The NSAID classification places Alvo among agents used to reduce swelling and discomfort. Unlike shorter-acting compounds in its class, Alvo (Oxaprozin) is clinically recognized for its relatively long elimination half-life, which supports a less frequent dosing regimen for sustained effect. This extended duration of action is a key distinguishing feature of Oxaprozin.


The Composition and General Purpose of Oxaprozin

The formulation of Alvo involves the active ingredient Oxaprozin combined with necessary excipients for reliable oral administration. The general therapeutic purpose of this compound is to achieve a triple effect: to act as an anti-inflammatory agent, an analgesic (pain reliever), and an antipyretic (fever reducer).

Oxaprozin performs these functions by inhibiting the synthesis of prostaglandins—chemical messengers that mediate pain and inflammation. By modulating this biological process, Alvo works throughout the body to alleviate general discomfort, including pain, stiffness, and swelling. This systemic relief contributes to improved physical comfort and joint mobility, such as easing the stiffness felt in the joints upon waking.

What side effects are possible with Alvo?

Possible Side Effects and Safety Information

The officially documented safety profile for Alvo (Oxaprozin, an NSAID) is categorized by the types and frequencies of adverse reactions observed, along with specific safety limitations from regulatory authorities.

Classification System-Organ Classes Involved
Common (ge 1% incidence) Gastrointestinal System, Nervous System, Skin and Subcutaneous Tissue, Renal System
Serious/Rare Risk Cardiovascular System, Hepato-biliary System, Hematologic System

Common Adverse Reactions (Gastrointestinal and CNS)

Reactions reported with the highest frequency in clinical trials often affect the digestive system (e.g., dyspepsia, diarrhea, constipation, nausea) and the nervous system (e.g., headache, dizziness, somnolence). Fluid retention (edema) and rash are also classified in the common incidence category.

Serious Adverse Reactions

Regulatory labeling highlights the risk of serious events that can occur without warning symptoms:

  • Cardiovascular Thrombotic Events: Increased risk of myocardial infarction (MI) and stroke, which can be fatal. This risk may increase with the duration of use.
  • Gastrointestinal Events: Risk of potentially fatal bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during treatment.
  • Other Serious Effects: Potential for severe hepatic (liver) injury, renal toxicity (kidney injury, particularly with long-term use), and severe allergic/skin reactions (e.g., SJS, TEN).

Population and Duration-Specific Safety Notes

The risk for serious gastrointestinal events is specifically noted as greater for older adults. The drug is contraindicated starting at 30 weeks gestation due to fetal risk. It is also restricted from use in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define the official overdose profile for Alvo (Oxaprozin) by detailing specific manifestations and mandatory emergency actions.

Documented Overdose Manifestations

Feature Regulatory Statements on Overdose Symptoms
Central Nervous System (CNS) Drowsiness, lack of energy, headache, dizziness, seizures, and loss of consciousness (coma) [NIH/MedlinePlus Drug Information].
Gastrointestinal (GI) Upset stomach, vomiting, stomach pain, bloody stools, black or tarry stools, and vomiting of material resembling coffee grounds [NIH/MedlinePlus Drug Information].

Severe Outcomes and Emergency Action

Overdosage is associated with severe risks, including fatal gastrointestinal ulceration, bleeding, and perforation, as well as the potential for acute renal failure and cardiovascular thrombotic events. Official guidance dictates that treatment should be symptomatic and supportive, as no specific antidote is known for this compound [FDA Labeling].

Immediate Emergency Action is required if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Individuals must immediately contact emergency services or the Poison Help line for severe or suspected overdose [NIH/MedlinePlus Drug Information].

Therapeutic Uses of Alvo

What Alvo Treats: Main Uses and Benefits

Alvo is applied across domains where additional symptomatic support is needed in contexts marked by increased discomfort or tension, which may assist with maintaining functional stability during episodes of heightened symptoms. The need for managing symptoms associated with acute or episodic changes is well-established, and this use is consistent with domains where additional symptomatic support is needed. This is in alignment with general therapeutic principles for short-term management.

Alvo is commonly used to help with symptoms that become more disruptive during flare-ups or periods of heightened physiological activity. It is relevant for easing symptoms related to physical discomfort and helps address symptom clusters that may become intense or disruptive. This supportive therapy is commonly used across conditions presenting with acute episodes, recurrent manifestations, and conditions characterized by periods of heightened symptoms.

Alvo contributes to easing the overall symptom load, which helps improve day-to-day comfort during symptomatic periods. This supportive role can provide help during episodes of increased distress or discomfort.

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning

Regulatory References

  1. European Medicines Agency guidance on acute pain relief

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Alvo (Oxaprozin) — Official Regulatory Information

Eligibility Scope

Classification Population Rule Status (Regulatory Wording)
Allowed Adults (Ages 18 and older) Approved for use
Allowed Pediatric patients (Ages 6 to 16 years) Approved for specific indications
Restricted Older Adults (Geriatric patients) Use with Caution
Not Recommended Children under 6 years of age Safety and effectiveness Not Established

Contraindications and Condition-Specific Limitations

Oxaprozin is Contraindicated for use in several populations, as documented in regulatory labeling:

  • Patients with known hypersensitivity to oxaprozin or a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • Patients undergoing peri-operative pain treatment in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Women who are 30 weeks gestation and later in pregnancy.

Use is Avoided in patients with advanced renal disease or severe heart failure unless the benefits outweigh the risks. Use is restricted in patients with severe hepatic dysfunction and requires careful consideration. Use during breastfeeding is Not Recommended, and a clinical decision must be made regarding continuing nursing or the drug.

What should I know about interactions with other medicines?

The official regulatory documents for Alvo (Oxaprozin) define a highly constrained interaction profile, primarily structured around additive pharmacodynamic risks and changes to co-administered drug concentrations.

Contraindicated Combinations

Alvo is contraindicated for treating peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. It is also prohibited for use in patients who have experienced allergic reactions, such as asthma or urticaria, after taking aspirin or other nonsteroidal anti-inflammatory drugs.

Pharmacodynamic and Bleeding Risks

The co-administration of Alvo with medications such as anticoagulants (like warfarin), antiplatelet drugs (including analgesic aspirin doses), corticosteroids, and SSRIs/SNRIs significantly increases the risk of serious gastrointestinal (GI) bleeding and hemorrhage. Using other NSAIDs simultaneously is not generally recommended due to this documented GI toxicity risk. Alvo also diminishes the antihypertensive and diuretic effects of ACE Inhibitors, ARBs, and Diuretics. This combination, particularly in the elderly or patients with impaired renal function, is noted as increasing the risk of worsening renal function.

Exposure-Altering Interactions

Alvo may modify the plasma exposure of co-administered drugs. It is documented to increase the serum concentrations of Digoxin and Lithium by reducing their renal clearance. Furthermore, Alvo displaces the plasma protein binding of Glyburide, which may lead to altered concentration levels. Alcohol ingestion and smoking are documented substance risk factors that heighten the potential for GI mucosal bleeding.

Mechanism of Action

How Alvo Works

Alvo's mechanism of action is primarily driven by targeted molecular interference that modulates three distinct physiological domains, leading to its characteristic physiological consequence.


Molecular Inhibition of Prostaglandin Synthesis

The fundamental mechanism of Alvo's active component, Oxaprozin, is the non-selective, competitive inhibition of Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, the drug suppresses the creation of prostaglandins, which are chemical mediators that help regulate the intensity of inflammatory and nociceptive signaling. This action directly modifies molecular steps that shape systemic physiological responses to inflammation and pain stimuli.


Central Thermoregulation and Tissue Accumulation

The inhibition of prostaglandin synthesis extends to the central nervous system, where it prevents the elevation of the hypothalamic thermoregulatory set point, leading to a mechanism that influences the regulation of body temperature. Additionally, the compound exhibits a physiological property of accumulating selectively within synovial joint fluid, which results in a distinct, prolonged local anti-inflammatory modulation within the synovial fluid.


COX-Independent Uric Acid Modulation

Uniquely, Alvo also exerts an action entirely independent of the COX pathway by modulating renal transporters in the kidney. This modulation enhances the physiological process of uric acid excretion, which alters the physiological balance of uric acid and results in its net renal clearance. This COX-independent effect engages mechanisms that influence metabolic pathways governing uric acid homeostasis.

Dosage and Administration Information

How to Use Alvo

The administration of Alvo (Oxaprozin) is based on standard clinical guidelines, focusing on high-level dosing rules and proper handling. As a nonsteroidal anti-inflammatory drug (NSAID) with a long duration of action, its usage pattern is defined by a primary once-daily (QD) schedule.

Official Administration Guidelines

Instruction Category Official Guideline
Route and Form Administered orally as a solid dosage form (caplet or capsule).
Standard Adult Dose The standard maintenance dose is 1200 mg once daily.
Maximum Dose The maximum recommended total daily intake is 1800 mg.
Timing Relative to Food May be taken with or without food.

Dosing Flexibility and Special Conditions

Alvo is intended to be used at the lowest effective dose for the shortest duration consistent with treatment goals. The dosing must be individualized based on the patient's response.

  • Divided Doses: While typically taken once daily, the dose may be split and taken in divided amounts if a patient experiences difficulty tolerating the full single dose.

  • Dose Adjustments: A lower starting dose of 600 mg once daily is designated for patients with low body weight or those with severe renal impairment or who are on dialysis. For pediatric patients (ages 6 to 16), the dose is calculated based on body weight.

  • Handling: The caplets or tablets must be swallowed whole and are not to be crushed, divided, or chewed before administration. Different strengths (e.g., 300 mg capsule vs. 600 mg caplet) are not considered interchangeable.

Recent Clinical Evidence

Alvo: Recent Clinical Evidence

Research evaluating Alvo for conditions like Osteoarthritis (OA) and Rheumatoid Arthritis (RA) was conducted primarily through short-term to intermediate-term Randomized Controlled Trials (RCTs). These studies monitored adult populations, with findings applied in research contexts involving episodic symptom patterns. Researchers examined outcomes related to physical discomfort, including changes in pain intensity scores, functional assessment scales, and objective signs like joint tenderness and swelling counts. Systematic reviews described patterns observed in the studies when compared against established nonsteroidal anti-inflammatory drugs (NSAIDs) and placebo. This evidence base is generally considered High-level based on the consistency of the available controlled trial data in evaluating defined symptomatic measures.


The evidence for use in Juvenile Rheumatoid Arthritis (JRA) was evaluated in pediatric patients (children aged 6 to 16 years). This evidence relies on a combination of specific studies focused on how the medicine behaves in children, combined with the extrapolation of findings from the robust adult RA research base. This reliance results in the evidence base being classified as Moderate-level.


A primary limitation in the research is the focus on symptom monitoring. Long-term outcomes related to joint structural changes or disease progression are not fully established by the existing controlled evidence, as follow-up durations were often limited. Furthermore, comparative evidence is lacking against some currently utilized therapeutic options, and findings specific to certain subgroups, such as older adults with multiple comorbidities, remain uncertain.

Key Studies & References NIH LiverTox: Nonsteroidal Anti-inflammatory Drugs (NSAIDs) - Reference for Mechanism of Action and Classification Consistency

Frequently Asked Questions (FAQ)

Common questions about Alvo (FAQ)


Q: What is the main thing Alvo is used for?

Official documents indicate that Alvo is used to help relieve the signs and symptoms of certain types of arthritis. This includes Osteoarthritis, Rheumatoid Arthritis, and Juvenile Rheumatoid Arthritis. It works by addressing the discomfort and inflammation associated with these conditions.


Q: How quickly should someone expect Alvo to start working?

While some people may notice pain relief within about an hour of administration, the full anti-inflammatory benefits may take longer to develop. Official product information suggests consistent use for several days, and sometimes up to a week or more, may be required to observe the complete effects.


Q: What are the most common side effects people report when taking Alvo?

According to regulatory documents, the most commonly reported side effects (incidence greater than 3%) include minor gastrointestinal issues like nausea, diarrhea, constipation, and indigestion (dyspepsia). A rash is also frequently reported by patients.


Q: What should I do if I forget a dose of Alvo?

If a dose is missed, official patient information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Regulatory warnings state that the dose should not be doubled.


Q: Why do people call Alvo by a different name sometimes?

Alvo is the original brand name for the active chemical component, which is called Oxaprozin. Regulatory bodies allow different companies to market this generic drug under various brand names once the original patent has expired.


Q: Is it normal to feel a change in sleep patterns after starting Alvo?

Official reporting indicates that changes in sleep patterns may occur. Both sleep disturbance, such as trouble sleeping, and somnolence, which is unusual drowsiness, are listed among the common side effects reported in clinical studies.


Q: Does Alvo have any effects on weight gain or loss?

Weight changes, including cases of rapid weight gain, have been reported as adverse events in clinical documentation. Patients should be aware that weight fluctuation may be associated with this medication.


Q: Is Alvo meant to cure a condition, or does it just manage symptoms?

Official descriptive language indicates that Alvo is used to manage and relieve the signs and symptoms of the conditions it treats. It is not intended to cure the underlying disease.


Q: Is it true that Alvo can cause mood changes?

Regulatory reports indicate that certain psychiatric side effects are possible. Both confusion and depression are listed among the common side effects reported during clinical use (incidence between 1% to 10%).


Q: What happens if I accidentally take two doses of Alvo too close together?

If a patient suspects that they have taken more than the prescribed amount of medication, regulatory patient information specifies that emergency medical attention or contacting a poison control line should occur if an overdose is suspected.


Q: Can Alvo make you feel tired or dizzy?

Yes, the official product information lists both dizziness and somnolence (unusual drowsiness or sleepiness) as common side effects. Patients should note that these effects may occur while taking the medication.


Q: How often do I need to see my healthcare provider while taking Alvo?

For patients using the medication long-term, official guidance indicates that frequent medical monitoring may be necessary. This typically includes periodic medical tests, such as blood work, to check for potential changes over time.


Q: Will taking Alvo change the results of blood tests?

Yes, official product information indicates that this medication may affect the results of certain laboratory tests. Official documentation notes that patients inform all laboratory personnel that they are taking this drug.


Q: Can I drive a car or operate machinery while taking Alvo?

Because common side effects include dizziness and somnolence (drowsiness), these effects may impact a person’s ability to think clearly or react quickly. Regulatory information indicates that potential impairment from these side effects may affect the ability to drive or operate machinery.


Q: Does Alvo carry a boxed warning from the FDA or similar agency?

Yes, the official regulatory labeling contains a Boxed Warning regarding serious health risks. These risks include the potential for increased serious cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation).


Q: Why might a patient need to stop taking Alvo?

Regulatory warnings indicate that the drug must be stopped if a patient experiences serious adverse events. These include signs of cardiovascular events, major gastrointestinal bleeding, indications of liver toxicity, or a severe allergic reaction.


Q: Does Alvo have an effect on appetite?

Loss of appetite is listed as a potential adverse event, though its incidence is not clearly defined in all documents. This symptom can also be an indication of other serious health issues, such as potential liver damage, and should be reported.


Q: Can men and women use Alvo equally, or are there gender-specific warnings?

The official label includes specific warnings directed at women regarding use during pregnancy. Due to the risk of fetal toxicity, use is advised to be limited between 20 and 30 weeks of gestation and must be avoided entirely from 30 weeks onward.


Q: How is Alvo packaged and what does the pill look like?

Alvo is available in different dosage forms, such as capsules and film-coated tablets. Official product information describes them by their physical characteristics, such as color, shape, and imprint code, which are used to help correctly identify the medication.


Q: Is Alvo a treatment that is taken for a long time?

Official guidance states that this medication should be used at the lowest effective dose for the shortest duration possible to achieve treatment goals. This recommendation is based on the fact that the risk of serious side effects, including cardiovascular events, may increase with the length of use.


Q: Can Alvo be used by children, and is the safety profile different?

Regulatory agencies have approved the drug for use in children aged 6 years and older for the treatment of Juvenile Rheumatoid Arthritis. Dosing is specialized for children and is calculated based on body weight.


Q: Is Alvo safe for older people, or are there a special warning for seniors?

Regulatory guidance advises caution when treating older adults (65 years and older). Official warnings note that elderly patients have a greater risk of experiencing serious gastrointestinal adverse events, such as bleeding, compared to younger adults.


Q: Are there any known foods or drinks that should be avoided while on Alvo?

Regulatory warnings specifically identify alcohol ingestion as a substance risk factor. Drinking alcohol while taking this medication can heighten the potential for serious gastrointestinal mucosal bleeding.


Q: How long does the effect of one dose of Alvo usually last?

The drug is categorized as having a long duration of action, which supports its typically recommended once-daily dosing schedule. This means that a single dose is designed to provide a prolonged effect.


Q: Does Alvo affect blood pressure or heart rate?

Official warnings list hypertension (high blood pressure) and heart failure as serious adverse events. Furthermore, regulatory information notes that patients on certain blood pressure medications may experience a diminished response to those therapies when taking Alvo.


Q: What organs in the body does Alvo mainly affect?

Based on regulatory warnings and precautions, the medication is known to affect several major organ systems. These include the gastrointestinal tract, the cardiovascular system (heart), and the kidneys and liver, all of which require monitoring during treatment.


Q: Is Alvo safe to take if I have liver or kidney problems?

Official guidance states that patients with kidney (renal) or liver (hepatic) impairment should be monitored closely during therapy. Use should be avoided in patients with advanced kidney disease unless the expected benefits are determined to outweigh the risk of worsening kidney function.


Q: What are the signs of a serious allergic reaction to Alvo?

Signs of a serious allergic reaction may include anaphylactic reactions, which can involve swelling of the face or throat and trouble breathing. The official label also lists hives (urticaria) and asthma attacks in patients known to be sensitive to aspirin.


Q: What is the maximum amount of time someone can safely take Alvo?

Regulatory warnings state that the medication should be used for the shortest duration possible, as the risk of serious side effects may increase over time. No specific maximum duration is officially defined in the labeling, emphasizing the principle of using the lowest effective dose for the shortest time needed.


Q: Are there any specific lifestyle changes recommended when starting Alvo?

The official product warnings identify smoking as a risk factor that increases the chance of serious gastrointestinal events, such as bleeding. Patients should be aware of this documented lifestyle risk factor associated with the drug.

How should Alvo be stored and disposed of?

How to Store and Dispose of Alvo (Oxaprozin)

Alvo must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be protected from light and moisture, kept in a tightly closed, light-resistant container, and must not be frozen or exposed to excessive heat.

Child Safety and Disposal

To prevent accidental ingestion, Alvo must be kept out of the reach of children, and the packaging should utilize a child-resistant closure. Unused or expired medication should not be flushed or discarded in wastewater. Consult a healthcare professional or follow local guidelines for proper disposal, utilizing a medicine take-back program if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alvo found in:

A-Z Index: